Anticonvulsants and antipsychotics in the treatment of bipolar disorder;Anticonvulsivantes e antipsicóticos no tratamento do transtorno bipolar

Revista Brasileira de Psiquiatria

Volumn 26, Issue SUPPL. 3, 2004, Pages 37-43

  Moreno, Ricardo Alberto ^a,b   Moreno, Doris Hupfeld ^a   Soares, Márcia Britto De Macedo ^a   Ratzke, Roberte ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Rua Capote Valente   (Brazil)

Author keywords

Anticonvulsivants therapeutic use; Antipsychotic agents therapeutic use; Bipolar disorder drug therapy

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; FLUOXETINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

AGRANULOCYTOSIS; ANOREXIA; ANTICONVULSANT THERAPY; APLASTIC ANEMIA; ATAXIA; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BLOOD DYSCRASIA; BREATHING DISORDER; CLINICAL TRIAL; CONFUSION; CONVULSION; DEPRESSION; DIPLOPIA; DIZZINESS; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPONATREMIA; LIVER FAILURE; LIVER TOXICITY; MANIA; NAUSEA; NEUROTOXICITY; PANCREATITIS; PARESTHESIA; PSYCHOPHARMACOTHERAPY; RASH; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TACHYCARDIA; TERATOGENICITY; TREMOR; VISUAL IMPAIRMENT; VOMITING;

EID: 7644233877     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-44462004000700009     Document Type: Review

References (89)

1. Lloyd AJ, Harrison CL, Ferrier IN, Young AH. The pharmacological treatment of bipolar affective disorder: practice is improving but could still be better. J Psychopharmacol. 2003;17(2):230-3.
2. Teng CT, Moreno RA. O papel do divalproato de sódio no tratamento dos transtornos do humor: eficácia, tolerabilidade e segurança. Rev Psiq Clin (São Paulo). 2002;29(1):42-53.
3. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000;57(5):481-9.
4. Goodwin FK. Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. J Clin Psychiatry. 2003;64 Suppl 5:18-24. Review.
5. Keck PE Jr, McElroy SL, Strakowski SM. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry. 1998;59 Suppl 6:74-82. Review.
6. Keck PE Jr, McElroy SL. Redefining mood stabilization. J Affect Disord. 2003;73(1-2):163-9. Review.
7. Harris M, Chandran S, Chakraborty N, Healy D. Mood-stabilizers: the archeology of the concept. Bipolar Disord. 2003;5(6):446-52.
8. a ed. Philadelphia: Lippincott Wiliams & Wilkins; c2000. p. 2289-99.
9. a ed. São Paulo: Lemos; 2001.
10. Keck PE Jr, McElroy SL, Tugrul KC, Bennet JA. Valproate oral loading in the treatment of acute mania. J Clin Psychiatry. 1993;54(8):305-8.
11. Bowden CL, Janicak PG, Orsulak P, Swann AC, Davis JM, Calabrese JR, et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry. 1996;153(6):765-70.
12. McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol. 1992;12(1 Suppl):42S-52S. Review.
13. Post RM, Ketter TA, Denicoff K, Pazzaglia PJ, Leverich GS, Marangell LB, et al. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology (Berl). 1996;128(2):115-29. Review.
14. West SA, Keck Jr. PE, McElroy SL. Valproate. In: Goodnick, PJ, editors. Mania: clinical and research perspectives. Washington (DC): American Psychiatric Press; 1998. p. 301-17.
15. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA. 1994;271(12):918-24.
16. Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry. 1990;147(4):431-4.
17. Swann AC, Bowden CL, Morris D, Calabrese JR, Petty F, Small J, et al. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry. 1997;54(1):37-42.
18. Strakowski SM, McElroy SL, Keck Jr PE. Clinical efficacy of valproate in bipolar illness: comparisons and contrasts with lithium. In: Halbreich U, Montgomery SA, editors. Pharmacotherapy For Mood, Anxiety And Cognitive Disorders. Washington (DC): American Psychiatric Press; 2000. p. 143-57.
19. Calabrese JR, Markovitz PJ, Kimmel SE, Wagner SC. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol. 1992;12(1 Suppl):53S-56S.
20. Stoll AL, Banov M, Kolbrener M, Mayer PV, Tohen M, Strakowski SM, et al. Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders. J Clin Psychopharmacol. 1994;14(5):311-3.
21. Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003;160(7):1263-71.
22. Geller B, Luby J. Child and adolescent bipolar disorder: a revievj of the past 10 years. J Am Acad Child Adolesc Psychiatry. 1997;36(9):1168-76.
23. Leinbenluft E. Issues in the treatment of women with bipolar illness. J Clin Psychiatry. 1997;58:Suppl 15:5-11. Review.
24. Iqbal MM, Gundiapalli SP, Ryan WG, Ryals T, Passman TE. Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants. South Med J. 2001;94(3):304-22. Review.
25. Chaudron LH, Jefferson JW. Mood stabilizers during breastfeeding: a review. J Clin Psychiatry. 2000;61(2):79-90. Review.
26. Noaghiul S, Narayan M, Nelson JC. Divalproex treatment of mania in elderly patients. Am J Geriatr Psychiatry. 1998;6(3):257-62.
27. Schulman KI, Herrmann N. The nature and management of mania in old age. Psychiatr Clin North Am. 1999;22(3):649-65, ix. Review.
28. a ed. Philadelphia: Lippincott Wiliams & Wilkins; c2000. p. 2299-304.
29. Moreno RA, Moreno DH. Novos anticonvulsivantes no tratamento do transtorno do humor bipolar: manejo clínico, eficácia e tolerância. Rev Psiq Clin(São Paulo). 1999;26:288-96.
30. Carta MG, Hardoy MC, Hardoy MJ, Grume H, Carpiniello B. The clinical use of gabapentin in bipolar spectrum disorders. J Affect Disord. 2003;75(1):83-91. Review.
31. Frye M, Ketter TA, Osuch EA, Kimbrell TA, Speer AM, Dunn RM, et al. Gabapentin and lamotrigine monotherapy in mood disorder: an update. American Psychiatric Association Annual Meeting, N77D:150; 1998.
32. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 2000;20(6):607-14.
33. Suppes T. Review of the use of topiramate for treatment of bipolar disorders. J Clin Psychopharmacol. 2002;22(6):599-609. Review.
34. Calabrese JR, Shelton MD, Rapport DJ, Kimmel SE. Bipolar disorders and the effectiveness of novel anticonvulsants. J Clin Psychiatry. 2002;63(Suppl 3):5-9. Review.
35. Calabrese JR. Topiramate versus placebo in mania. Presented at the 153 Annual Meeting of the American Psychiatric Association, Chicago; 2000.
36. Hussain MZ, Chaudry ZA, Hussain S. Topiramate in treatment refractory bipolar depression [abstract]. Bipolar Disord. 2001;3(1):43.
37. McIntyre RS, Mancini DA, McCann SM, et al. Randomized, single-blind comparison of topiramate and bupropion SR as add-monotherapy in bipolar depression [abstract]. Bipolar Disord. 2001;3(1):47.
38. a ed. Philadelphia: Lippincott Williams & Wilkins; c2000.
39. Licht RW, Vestergaard P, Kessing LV, Larsen JK, Thomsen PH: Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Psychopharmacological treatment with lithium and antiepileptic drugs: suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Acta Psychiatr Scand. 2003;(419):1-22.
40. Ketter TA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS, et al. Carbamazepine. In: Goodnick PJ, editor. Mania: Clinical and Research Perspectives. Washington DC, American Psychiatric Press; 1998. p. 263-300
41. Soares MBM, Almeida KM, Moreno RA. Tratamento médico- clínico. In: Transtorno Bipolar do Humor. Moreno RA, Moreno DH, editores. São Paulo: Lemos Editorial; 2002.
42. Hartong EG, Moleman P, Hoogduin CA, Broekman TG, Nolen WA; LitCar Group. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry. 2003;64(2):144-51.
43. Kleindienst N, Greil W. Inter-episodic morbidity and drop-out under Carbamazepine and lithium in the maintenance treatment of bipolar disorder. Psychol Med. 2002;32(3):493-501.
44. Barrett C, Richens A. Epilepsy and pregnancy. Report of an Epilepsy Research Foundation Workshop. Epilepsy Res. 2003;52(3):147-87. Review.
45. Matalon S, Schechtman S, Goldzweig G, Ornoy A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol. 2002;16(1):9-17.
46. Eastham JH, Jeste DV, Young RC. Assessment and treatment of bipolar disorder in the elderly. Drugs Aging. 1998;12(3):205-24. Review.
47. White HS. Mechanism of action of newer anticonvulsants. J Clin Psychiatry. 2003;64(Suppl 8):5-8.
48. Centorrino F, Albert MJ, Berry JM, Keileher JP, Fellman V, Line G, et al. Oxcarbazepine: clinical experience with hospitalized psychiatric patients. Bipolar Disord. 2003;5(5):370-4. Review.
49. Ghaemi SN, Ben DA, Klugman J, Rosenauist KJ, Hsu DJ. Oxcarbazepine treatment of bipolar disorder. J Clin Psychiatry. 2003;64(8):943-5.
50. Sussman N. Anticonvulsants: Other anticonvulsants. In: Sadock BJ, Sadock VA, ediitors. Kaplan & Sadock's comprehensive textbook of psychiatry. 7. ed. Philadelphia: Lippincott Williams & Wilkins; c2000.
51. Calabrese JR, Sullivan JR, Bowden CL, Suppes T, Goldberg JF, Sachs GS, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry. 2002;63(11):1012-9. Review.
52. Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry. 2000;12(1):5-10.
53. Berk M. Lamotrigine and the treatment of mania in bipolar disorder. Eur Neuropsychopharmacol. 1999;9 Suppl 4:5119-23. Review.
54. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan ET, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999;60(2):79-88.
55. Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry. 2000;61(11):841-50.
56. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, et al. A placebo-controlted 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60(4):392-400.
57. Calabrese JR, Vieta E, Shelton MD. Latest maintenance data on lamotrigine in bipolar disorder. Eur Neuropsychopharmacol. 2003;13(Suppl 2):S57-66. Review.
58. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64(9):1013-24.
59. Chouinard G, Young SN, Annable L. Antimanic effect of clonazepam. Biol Psychiatry. 1983;18(4):451-66.
60. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 1982;39(4):473-81. Review.
61. Curtin F, Schulz P. Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis. J Affect Disord. 2004;78(3):201-8.
62. Chouinard G. Clonazepam in acute and maintenance treatment of bipolar affective disorder. J Clin Psychiatry. 1987;48 Suppl:29-37. Review.
63. Winkler D, Willeit M, Wolf R, Stamenkovic M, Tauscher J, Pjrek E, et al. Clonazepam in the long-term treatment of patients with unipolar depression, bipolar and schizoaffective disorder. Eur Neuropsychopharmacol. 2003;13(2):129-34.
64. Licht RW. Drug treatment of mania: a critical review. Acta Psychiatr Scand. 1998;97(6):387-97. Review.
65. a ed. São Paulo: Lemos, 2002. p. 115-39.
66. McElroy SL, Keck PE Jr. Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry. 2000;48(6):539-57. Review.
67. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002;159(7):1146-54.
68. Tohen M, Goldberg JF, Gonzalez-Pinto AM, Azorin JM, Vieta E, Hardy-Bayle MC, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003;60(12):1218-26.
69. Barbini B, Scherillo P, Benedetti F, Crespi G, Colombo C, Smeraldi E. Response to clozapine in acute mania is more rapid than that of chlorpromazine. Int Clin Psychopharmacol. 1997;12(2):109-12.
70. Green AI, Tohen M, Patel JK, Banov M, DuRand C, Berman I, et al. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry. 2000;157(6):982-6.
71. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomized controlled trial. Br J Psychiatry. 2003;182:141-7.
72. Strakowski SM. Clinical update in bipolar disorders: second-generation antipsychotics in the maintenance therapy of bipolar disorder. Medscape. 2003 Jun [cited 2004 March 5]. Available from: URL: http:// www.medscape.com/ viewprogram/2496_pnt.
73. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999;156(5):702-9.
74. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry. 2000;57(9):841-9.
75. Tohen M, Chengappa KN, Suppes T, Zarate CA Jr, Calabrese JR, Bowden CL et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59(1):62-9.
76. Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002;159(6):1011-7.
77. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety, and tolerabillty of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2002;63(12):1148-55.
78. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K; Ziprasidone in Mania Study Group. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160(4):741-8.
79. Keck PE Jr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160(9):1651-8.
80. Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002;41(10):1216-23.
81. Zarate CA Jr, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry. 2004;161(1):169-71.
82. Sernyak MJ, Woods SW. Chronic neuroleptic use in manic-depressive illness. Psychopharmacol Bull. 1993;29(3):375-81. Review.
83. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079-88.
84. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry. 1999;156(8):1164-9.
85. Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003;160(7):1263-71.
86. Tohen M, Bowden CL, Calabrese JR. Olanzapine versus placebo for relapse prevention in bipolar disorder. Poster presented at the 156th APA Annual Meeting; May 17-22, 2003; San Francisco, California; 2003.
87. Tohen M, Marnernos A, Bowden C. Olanzapine versus lithium in relapse prevention in bipolar disorder . Poster presented at the 156th APA Annual Meeting; May 17-22, 2003; San Francisco, California; 2003.
88. Pinkofsky HB. Effects of antipsychotics on the unborn child: what is known and how should this influence prescribing? Pediatr Drugs. 2000;2(2):83-90. Review.
89. Zarate CA Jr, Quiroz JA. Combination treatment in bipolar disorder: a review of controlled trials. Bipolar Disord. 2003;5(3):217-25. Review.